In Synapse February 2013, Taylor Wessing discusses the issue of interim injunctions against pharmaceutical patent infringement. Synapse focuses on law for the life sciences industry.
The patent system gives innovators a monopoly right — a right that in the life science and pharmaceutical sector can be extremely valuable. It is perhaps unsurprising therefore that a manufacturer will go to some lengths to enforce their patent rights protecting a product.
A powerful tool for this purpose is the injunction, which — if deployed correctly — can stop a potential infringer in their tracks.
Other topics covered in Synapse February 2013 include: the Transparency Directive and the customs regulation.
To read more click here.